Martínez PS

Language: Spanish
References: 9
Page: 1-3
PDF size: 175.88 Kb.

Text Extraction

No abstract.

REFERENCES

1. Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019[acceso: 26/11/2019];11(8). Disponible en: https://www.ncbi.nih.gov

2. Park J, Park HJ. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins (Basel). 2017;9(9). Doi: https://doi.org/10.3390/toxins9090260

3. Park J, Chung ME. Botulinum Toxin for Central Neuropathic Pain. Toxins (Basel). 2018;10(6).

4. Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15(6):555-65.

5. Jain P, Jain M, Jain S. Subcutaneous Injection of Botulinum Toxin in Patients with Post Herpetic Neuralgia. A Preliminary Study. J Assoc Physicians India. 2018;66(7):48-49.

6. Puentes Gutiérrez AB, García Bascones M, Puentes Gutiérrez R, Díaz Jiménez M. Subcutaneous botulinum toxin in the treatment of peripheral neuropathic pain. Rehabilitación (Madr). 2019;53(2):131-35.

7. Sousa EJS, Sousa GC, Baia VF, Somensi DN, Xavier MB. Botulinum toxin type A in chronic neuropathic pain in refractory leprosy. Arq Neuropsiquiatr. 2019;77(5):346-51.

8. Salehi H, Moussaei M, Kamiab Z, Vakilian A. The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: A randomized double-blind clinical trial. Iran J Neurol. 2019;18(3):99-107.

9. Moreno Hay I, Mishra P, Okeson JP. Intraoral Administration of Botulinum Toxin for Continuous Dentoalveolar Neuropathic Pain: A Case Series. J Oral Facial Pain Headache. 2019;33(2):160-64.